Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, entered an agreement with Laboratory Corporation of America Holdings to validate biomarkers for its lead focal adhesion kinase inhibitor VS-6063 in the development of an applicable ... (more)
http://www.laboratorynetwork.com/doc.mvc/verastem-biomarker-labcorp-cancer-stem-cell-agent-companion-diagnostic-0001?atc~c=771+s=773+r=001+l=a
http://www.laboratorynetwork.com/doc.mvc/verastem-biomarker-labcorp-cancer-stem-cell-agent-companion-diagnostic-0001?atc~c=771+s=773+r=001+l=a
No comments:
Post a Comment